Teva Pharma Files 8-K on Operations and Financials
Ticker: TEVJF · Form: 8-K · Filed: Jul 31, 2024 · CIK: 818686
| Field | Detail |
|---|---|
| Company | Teva Pharmaceutical Industries Ltd (TEVJF) |
| Form Type | 8-K |
| Filed Date | Jul 31, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: sec-filing, financial-reporting
Related Tickers: TEVA
TL;DR
Teva filed an 8-K on July 31, 2024, updating investors on its financial condition and operations.
AI Summary
On July 31, 2024, Teva Pharmaceutical Industries Ltd. filed an 8-K report to disclose information regarding its results of operations and financial condition, as well as financial statements and exhibits. The filing does not contain specific financial figures or operational details within the provided text, but indicates a formal reporting event.
Why It Matters
This 8-K filing signals that Teva Pharmaceutical Industries Ltd. is providing updated information to the SEC regarding its financial performance and operational status, which is crucial for investors to assess the company's health.
Risk Assessment
Risk Level: low — The filing is a standard disclosure and does not contain any immediate negative news or significant changes.
Key Players & Entities
- TEVA PHARMACEUTICAL INDUSTRIES LTD (company) — Registrant
- July 31, 2024 (date) — Date of Report
FAQ
What specific financial information is being disclosed in this 8-K filing?
The provided text indicates the filing pertains to 'Results of Operations and Financial Condition' and 'Financial Statements and Exhibits,' but does not detail specific financial figures.
What is the primary purpose of this 8-K filing for Teva Pharmaceutical Industries Ltd.?
The primary purpose is to formally report to the SEC on its results of operations and financial condition, and to include relevant financial statements and exhibits.
When was this 8-K report filed with the SEC?
The report was filed on July 31, 2024.
What is Teva Pharmaceutical Industries Ltd.'s principal executive office address?
The principal executive office is located at 124 Dvora Hanevi’a Street, Tel Aviv 6944020, Israel.
What is Teva Pharmaceutical Industries Ltd.'s telephone number?
The registrant's telephone number is +972 - 3-914-8213.
Filing Stats: 518 words · 2 min read · ~2 pages · Grade level 12.8 · Accepted 2024-07-31 07:00:57
Filing Documents
- f8k_073124.htm (8-K) — 15KB
- exh_991.htm (EX-99.1) — 548KB
- 0001171843-24-004270.txt ( ) — 801KB
- gnw-20190101.xsd (EX-101.SCH) — 3KB
- gnw-20190101_def.xml (EX-101.DEF) — 25KB
- gnw-20190101_lab.xml (EX-101.LAB) — 33KB
- gnw-20190101_pre.xml (EX-101.PRE) — 22KB
- f8k_073124_htm.xml (XML) — 3KB
02. Results of Operations and Financial Condition
Item 2.02. Results of Operations and Financial Condition. On July 31, 2024, Teva Pharmaceutical Industries Ltd. issued a press release announcing its financial results for the period ended June 30, 2024. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and the information contained therein is incorporated herein by reference. The information included in this Item 2.02 is being furnished to the Securities and Exchange Commission and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description of Document 99.1 Teva Reports 2024 Second Quarter Financial Results
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. TEVA PHARMACEUTICAL INDUSTRIES LIMITED Date: July 31, 2024 By: /s/ Eli Kalif Eli Kalif Executive Vice President, Chief Financial Officer